GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Shiller PE Ratio

TG Therapeutics (STU:NKB2) Shiller PE Ratio : (As of May. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


TG Therapeutics Shiller PE Ratio Historical Data

The historical data trend for TG Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Shiller PE Ratio Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TG Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TG Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, TG Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Shiller PE Ratio falls into.



TG Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

TG Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, TG Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.064/131.7762*131.7762
=-0.064

Current CPI (Mar. 2024) = 131.7762.

TG Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.265 100.560 -0.347
201409 -0.396 100.428 -0.520
201412 -0.389 99.070 -0.517
201503 -0.323 99.621 -0.427
201506 -0.339 100.684 -0.444
201509 -0.249 100.392 -0.327
201512 -0.340 99.792 -0.449
201603 -0.251 100.470 -0.329
201606 -0.294 101.688 -0.381
201609 -0.445 101.861 -0.576
201612 -0.455 101.863 -0.589
201703 -0.486 102.862 -0.623
201706 -0.401 103.349 -0.511
201709 -0.403 104.136 -0.510
201712 -0.389 104.011 -0.493
201803 -0.478 105.290 -0.598
201806 -0.505 106.317 -0.626
201809 -0.369 106.507 -0.457
201812 -0.607 105.998 -0.755
201903 -0.381 107.251 -0.468
201906 -0.372 108.070 -0.454
201909 -0.627 108.329 -0.763
201912 -0.396 108.420 -0.481
202003 -0.439 108.902 -0.531
202006 -0.417 108.767 -0.505
202009 -0.620 109.815 -0.744
202012 -0.584 109.897 -0.700
202103 -0.580 111.754 -0.684
202106 -0.490 114.631 -0.563
202109 -0.553 115.734 -0.630
202112 -0.620 117.630 -0.695
202203 -0.463 121.301 -0.503
202206 -0.284 125.017 -0.299
202209 -0.263 125.227 -0.277
202212 -0.368 125.222 -0.387
202303 -0.262 127.348 -0.271
202306 -0.314 128.729 -0.321
202309 0.684 129.860 0.694
202312 -0.092 129.419 -0.094
202403 -0.064 131.776 -0.064

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TG Therapeutics  (STU:NKB2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


TG Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics (STU:NKB2) Business Description

Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines